Weller, Johannes and Schaefer, Niklas and Schaub, Christina and Potthoff, Anna-Laura and Steinbach, Joachim P. and Schlegel, Uwe and Sabel, Michael and Hau, Peter and Seidel, Clemens and Krex, Dietmar and Goldbrunner, Roland and Pietsch, Torsten and Tzaridis, Theophilos and Zeyen, Thomas and Borger, Valeri and Guresir, Erdem and Vatter, Hartmut and Herrlinger, Ulrich and Schneider, Matthias (2022) Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. JOURNAL OF NEURO-ONCOLOGY, 159 (1). pp. 95-101. ISSN 0167-594X, 1573-7373
Full text not available from this repository. (Request a copy)Abstract
Purpose The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy. Methods The impact of obesity (BMI >= 30 kg/m(2)) on overall survival (OS) and progression-free survival (PFS) was investigated with Kaplan-Meier analysis and log-rank tests. A multivariable Cox regression analysis was performed including known prognostic factors as covariables. Results Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7-30.8) vs. 43.2 (32.5-54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8-18.9) vs 17.6 (14.7-20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53-4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm. Conclusion Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BODY-MASS INDEX; SURVIVAL; TEMOZOLOMIDE; ASSOCIATION; PARADOX; HYPERGLYCEMIA; MORTALITY; BENEFIT; DAMAGE; Glioblastoma; Temozolomide; Obesity; MGMT |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 08 Feb 2024 13:20 |
| Last Modified: | 08 Feb 2024 13:20 |
| URI: | https://pred.uni-regensburg.de/id/eprint/57868 |
Actions (login required)
 |
View Item |
